David Woodhouse, NGM CEO
Merck partner NGM Bio takes stock beating after PhII failure in late-stage eye disease
NGM Bio just found itself on the bad end of a clinical trial readout, and investors are responding harshly.
The San Francisco biotech and long …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
